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Role of histone acetylation in the activity-dependent regulation
of sulfiredoxin and sestrin 2
Francesc X. Soriano, Sofia Papadia, Karen F.S. Bell, and Giles E. Hardingham*
Centre for Integrative Physiology; University of Edinburgh; Edinburgh, SCT UK
Abstract
Peroxiredoxins are neuroprotective antioxidant enzymes that reduce hydroperoxides and protect
neurons against oxidative stress. However, they can be inactivated through hyperoxidation of their
active site cysteine, an event that can take place in the brain in response to oxidative insults such
as stroke and also normal aging. Synaptic activity promotes the reduction of hyperoxidized
peroxiredoxins in neurons, and induces the expression of sulfiredoxin (Srxn1) and sestrin 2
(Sesn2) which have been reported to mediate this. We have investigated the importance of histone
acetylation in the regulation of these genes, to understand more about how these genes are
regulated by synaptic activity.
We show that the sestrin 2 promoter undergoes activity-dependent histone acetylation, which
contributes to its transcriptional activation. In contrast, promoter-proximal histone acetylation is
not involved in the activity-dependent induction of sulfiredoxin. Nevertheless, expression of both
sestrin 2 and sulfiredoxin can be induced by enhancing histone acetylation through treatment of
neurons with the histone deacetylase inhibitor trichostatin A (TSA). Furthermore, protective doses
of TSA inhibit the formation of hyperoxidized peroxiredoxins in neurons exposed to oxidative
insults. Histone deacetylases are emerging therapeutic targets in neurodegenerative disorders
associated with oxidative stress. Our results indicate that manipulating the histone acetylase-
deacetylase balance in neurons may mimic the effects of synaptic activity in preventing the
oxidative inactivation of peroxiredoxins.
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Introduction
Peroxiredoxins (Prxs) are a ubiquitous family of thiol-based antioxidative enzymes.1-3 The
2-cysteine (2-Cys) Prxs is the predominant Prx subfamily, comprising Prx I-IV.4 Prxs have
cytoprotective effects in the face of oxidative insults in a variety of cell types.1,5,6 PrxII
protects PC12 cells against trophic deprivation-induced apoptosis7 and protects cortical
neurons against Aβ toxicity.8 PrxIII protects hippocampal neurons against excitotoxicity.2
Antisense against PrxII renders neuroblastoma cells vulnerable to oxidative stress,3 and
knock-down of PrxII renders cortical neurons vulnerable to MPP+ treatment.9
Overexpression of PrxII protects neurons against ischemia in vitro.10
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Prxs contain a peroxidatic cysteine residue at the heart of their active site which catalyses
the reduction of hydroperoxides, becoming oxidized to cysteine sulfenic acid (-SOH) in the
process. Cys-SOH then forms a disulfide bond with the resolving cysteine, which is in turn
reduced by thiol-based reducing enzymes, principally thioredoxin.4 Sometimes, under
increased oxidative stress, Prx-SOH is further oxidized by peroxide to sulfinic (-SO2H) acid,
causing inactivation of peroxidase activity.11 Prx hyperoxidation to Prx-SO2H takes place
in neurons undergoing oxidative death in vitro, and is associated with ischemic brain
damage in vivo as well as normal aging.12,13 Prx-SO2H is not a substrate for the resolving
cysteine and cannot be reduced by thioredoxin. As such, Prx hyperoxidation to Prx-SO2H
was thought to be irreversible. However, it was subsequently found that Prx-SO2H can be
reduced back to the catalytically active thiol form by two ATP-dependent reductases,
sulfiredoxin (Srxn1)14-16 and sestrin 2 (Sesn2).17 We recently found that both sulfiredoxin
and sestrin 2 are inducible genes whose expression is rapidly triggered by synaptic activity.
12 Synaptic activity also promoted the reduction of hyperoxidized Prx and protection
against peroxide-induced death.12 The strong inducibility of both sestrin 2 and sulfiredoxin
essentially means that neuronal Prx-SO2H-reducing capacity can be switched on or off by a
variety of signals.12,18 Since knockdown studies causally linked these genes to
neuroprotection,12 pharmacological manipulation of their transcription may be of
therapeutic benefit in disorders associated with oxidative damage.
The regulation of transcription is a complicated process, but a key level of control is in the
post-translational modification of promoter-proximal histones.19,20 It is generally true that
an increase in histone acetylation promotes transcriptional activation through the relaxation
of chromatin structure.19,21 The degree of histone acetylation at any one locus is controlled
by the balance of histone acetyl transferases (HATs) and histone deacetylases (HDACs).
Changes in histone acetylation are observed in response to learning paradigms, recreational
drug exposure, environmental enrichment and seizure activity.22-25 As well as a role for
histone acetylation changes in physiological processes, inappropriate histone acetylation
(particularly hypoacetylation) may contribute to several CNS disorders by causing aberrant
transcription within neurons.26,27 As a result, histone deacetylase inhibitors are emerging
as potential therapies for a number of neurodegenerative diseases and syndromes, including
Huntington disease, motor-neuron disease, fragile X syndrome and Friedreich ataxia.27-31
In vitro, inhibition of HDACs prevents oxidative neuronal death of embryonic cortical
neurons29 by a mechanism independent of the glutathione pathway.29 It is not clear
whether more mature neurons are also protected by HDAC inhibition.
Here we have investigated the role of histone acetylation in regulating the basal and activity-
induced expression of sulfiredoxin and sestrin 2, which can reverse the hyperoxidation of
Prxs. We find that histone acetylation plays an important role in the activity-dependent
induction of sestrin 2, but not sulfiredoxin. Nevertheless, expression of both genes can be
induced by elevating global histone acetylation levels by pharmacological inhibition of class
I and II histone deacetylases.
Results
Synaptic activity triggers acetylation of histone H4 at the sestrin 2 promoter, but not the
sulfiredoxin promoter
To investigate the importance of promoter-proximal histone acetylation in the activity-
dependent induction of sestrin 2 and sulfiredoxin expression, we wanted to know whether
promoter-specific histone acetylation takes place in response to synaptic activity. We used
the established method of network disinhibition to enhance synaptic activity, by applying the
GABAA receptor antagonist bicuculline, and the K+ channel antagonist 4-aminopyridine
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(which enhances burst frequency, hereafter BiC/4-AP32,33). As expected, expression of
sulfiredoxin and sestrin 2 were strongly induced by BiC/4-AP treatment (Fig. 1A and B).
Signal-dependent acetylation of histones normally occurs on histones H3 and H4.19 We
decided to study histone H4 acetylation, since increases in this modification are readily
detectable in neurons at inducible genes, in response to signalling events.20,34 We
performed chromatin-immunoprecipitation (ChIP) with an anti-acetyl H4 antibody on
extracts taken from control and BiC/4-AP-treated neurons. We then performed PCR on the
immunoprecipitated DNA using primers spanning the promoter regions of sestrin 2,
sulfiredoxin and also Txnip, a gene whose expression is suppressed by synaptic activity.12
Using this technique, we found that BiC/4-AP treatment caused a consistently large increase
in H4 acetylation at the sestrin 2 promoter in each of four independent experiments (Fig. 1C
and F). In contrast, no significant increase was observed at the sulfiredoxin promoter (Fig.
1D and F), nor in the promoter of Txnip (Fig. 1E and F). Thus, sulfiredoxin and sestrin 2,
two genes induced to a similar extent by synaptic activity, appear to differ in the degree to
which their promoters become acetylated at histone H4. This is consistent with the idea that
activity-dependent histone acetylation is a specific, targeted event, rather than a globally
induced effect. Indeed, we found that promoting synaptic activity with BiC/4-AP treatment
did not cause a global increase in histone H3 or H4 acetylation, as assayed by western blot
analysis with anti acetyl H3 and H4 antibodies (Fig. 1G).
Histone acetylation plays a role in the activity-dependent induction of sestrin 2 expression
The above results indicate that synaptic activity triggers promoter-proximal histone
acetylation of the sestrin 2 gene which may contribute to its enhanced transcription. To test
this specifically, we first investigated whether inducing histone acetylation is sufficient to
cause an increase in sestrin 2 expression. Histone acetylation in neurons was induced by
inhibition of class I and II histone deacetylases by trichostatin A (TSA). As expected,
treatment of cortical neurons with TSA resulted in a global increase in histone H3 and H4
acetylation, as assayed by western blot (Fig. 2A). TSA treatment resulted in significant
induction of Sestrin 2 mRNA (Fig. 2B). Thus, elevation of histone acetylation is sufficient to
induce sestrin 2 expression.
We next investigated whether increased histone acetylation plays a role in the transcriptional
activation of sestrin 2 by synaptic activity. To do this, we determined the extent to which
TSA promoted expression of sestrin 2 in neurons experiencing high levels of synaptic
activity. We reasoned that if synaptic activity was promoting gene expression by enhancing
promoter-proximal histone acetylation, then the effect of TSA would be occluded by the
effect of synaptic activity. We found that in BiC/4-AP treated neurons, where sestrin 2
expression is high (Fig. 1A), TSA treatment failed to further induce sestrin 2 expression
(Fig. 2C). Thus, the strong induction of sestrin 2 by TSA treatment [observed in electrically
quiet neurons (Fig. 2B)] is completely occluded by synaptic activity. This indicates that
synaptic activity induces sestrin 2 expression in part by promoting promoter histone
acetylation.
Histone acetylation is not involved in the activity-dependent induction of sulfiredoxin
expression
The absence of an observed increase in histone H4 acetylation accompanying the activity-
dependent induction of sulfiredoxin expression (Fig. 1D) indicated that histone acetylation
may not be involved in the induction of this gene by synaptic activity. However, this
possibility could not be ruled out. To investigate this further we studied the influence of
TSA on sulfiredoxin expression in both electrically quiet and synaptically active neurons.
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Treatment of neurons with TSA led to a significant induction of sulfiredoxin mRNA (Fig.
3A). This demonstrates that enhancing histone acetylation is sufficient to induce
sulfiredoxin expression, just as it is sufficient to induce sestrin 2 expression. However, this
induction of sulfiredoxin by TSA treatment was not occluded by synaptic activity: TSA still
induced sulfiredoxin expression in BiC/4-AP stimulated neurons (Fig. 3B). This suggests
that synaptic activity and TSA induce sulfiredoxin expression by different pathways i.e., that
histone acetylation is not involved in the activity-dependent induction of sulfiredoxin
expression, consistent with the absence of an increase in histone H4 acetylation following
synaptic activity (Fig. 1D).
Protective doses of TSA inhibit the formation of hyperoxidized Prxs
The therapeutic application of histone deacetylase inhibitors has been suggested for a variety
of diseases of the nervous system, many of which are associated with oxidative stress.26
Despite a differential role for histone acetylation in the activity-dependent induction of
sulfiredoxin and sestrin 2 expression, both genes are induced by TSA. This raises the
possibility that the reduction of hyperoxidized Prxs could be promoted by this
pharmacological intervention. We first wanted to confirm that the induction of sestrin 2 and
sulfiredoxin mRNA by TSA treatment led to an upregulation in protein expression. Western
analysis revealed this to be the case: expression of both proteins were induced by TSA (Fig.
4A). We then tested the ability of TSA to inhibit the formation of hyperoxidized Prxs, using
western analysis employing an antibody specific for the hyperoxidized form of Prx. We
applied a brief dose of H2O2 to induce Prx hyperoxidation and then looking for reduction of
this after H2O2 washout. We focussed on a band that we believe to be PrxII, the major
neuronal cytosolic Prx.35,36 As reported previously, unstimulated neurons did not exhibit
significant reduction in Prx-SO2H levels 16 h after washout, while synaptic activity evoked
by BiC/4-AP treatment promotes a reduction of Prx-SO2H levels (Fig. 4B and C; and
reviewed in ref. 12). Strikingly, TSA pre-treatment for 8 h also promoted a significant
reduction in Prx-SO2H levels following washout (Fig. 4B and C). Further biochemical
analysis would be required to determine for sure whether this reflects actual reduction of the
Prx-SO2H form of Prx. Moreover, other experiments are required to determine whether
induction of sulfiredoxin and/or sestrin 2 is responsible for these effects. Of note, HDAC6
inhibition has recently been reported to induce N-acetylation of Prx I and II, increasing
resistance to hyperoxidation.37 This offers an alternative explanation as to why TSA
treatment inhibits formation of hyperoxidized Prxs.
Finally, we wanted to know whether the TSA-induced changes outlined above are associated
with reduced neuronal death following challenge with an oxidative insult. TSA has been
shown to protect against oxidative neuronal death in embryonic E17 neurons cultured for 1–
2 days in vitro.29 However, the neurons used in this study are more mature (E21 cortical
neurons cultured for 8–10 days in vitro). We found that 8 h TSA pre-treatment resulted in
far lower levels of peroxide-induced apoptosis compared to control (Fig. 4D). Thus,
enhancing histone acetylation levels protects neurons against oxidative insults in our system,
as well as upregulating expression of sulfiredoxin and sestrin 2.
Discussion
Although synaptic activity promotes the expression of a large number of genes, knowledge
of the role of dynamic changes in histone acetylation in the induction of individual genes is
incomplete. We have found that two activity-induced genes, one or both of which contribute
to enhanced antioxidant defenses, differ markedly in terms of the role of histone acetylation
in their induction by synaptic activity.
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Activity-dependent regulation of sulfiredoxin via AP-1 is independent of histone
acetylation
Sulfiredoxin has demonstrable cytoprotective and antioxidative effects in diverse cells
including neurons and lung epithelial cells.12,38,39 A study of the transcriptional regulation
of sulfiredoxin in neurons revealed that it could be controlled by AP-1 via two cis-acting
AP-1 consensus sites.12 Mutation of each AP-1 site in turn reduced transcriptional
activation of sulfiredoxin by synaptic activity, and mutation of both sites abolished induction
completely.12 Also, expression of the widely-used inhibitor of AP-1-mediated gene
expression, TAM67 (a dominant-negative form of c-Jun40) inhibited synaptic activity-
dependent induction of the sulfiredoxin promoter in neurons.18 The direct regulation of
sulfiredoxin by AP-1 acting via these two sites was confirmed in the context of mouse
epidermal cells. Here it was shown that 12-O-tetradecanoylphorbol-13-acetate (TPA)-
mediated induction of sulfiredoxin was stimulated by AP-1 acting on these sites.41 Our
findings indicate that histone acetylation is not involved in the activity-dependent induction
of sulfiredoxin. Activity-evoked signals that result in the activation or expression of AP-1
can clearly promote transcription independent of acetylation. Despite this, TSA is still able
to induce sulfiredoxin: this may either be via the direct acetylation of the sulfiredoxin
promoter, or conceivably due to the induction of AP-1 transcription factor expression. For
example, TSA is known to induce c-fos expression in neurons,42 which could conceivably
feed back onto the sulfiredoxin promoter. Alternatively, the induction of sulfiredoxin
expression by TSA treatment may be independent of AP-1. Sulfiredoxin is also subject to
transcriptional regulation by Nuclear factor erythroid 2-related factor (Nrf2) acting via an
antioxidant response element.18,39 Nrf2 acts at these elements as a heterodimer with small
Maf proteins.43 Under basal conditions, when Nrf2 is inactive, Maf heterodimerizes with
Bach1 and exerts active repression of target genes. Thus, TSA could be interfering with the
activity of the corepressor complex recruited by Maf/Bach1 heterodimers.
Histone acetylation-dependent induction of the C/EBPβ target gene sestrin 2
The transcriptional activation of sestrin 2 by synaptic activity is mediated by C/EBPβ, acting
via two sites in the promoter. Evidence presented here suggests that this induction mediated
by C/EBPβ may involve derepression of the sestrin 2 promoter through enhanced histone
acetylation. The strong sensitivity of basal levels of sestrin 2 to changes in histone
acetylation suggest that it may ordinarily be subject to active suppression through promoter
deacetylation. C/EBPβ is repressed by the corepressor SMRT44 which is known to recruit a
number of histone deacetylases to transcription factors with which it interacts,45 indicating
that it could be capable of mediating such suppression under basal conditions. Following
synaptic activity, however, SMRT is exported from the nucleus46 so any SMRT-mediated
repression would be abolished. Treatment of neurons with TSA also causes SMRT
redistribution46 and in any case would prevent SMRT-associated HDACs from working.
Interestingly, sestrin 2 was recently found to have a novel role in mediating the arrest of
cellular proliferation in response to genotoxic insults by preventing mTOR signaling47 and
so its induction by HDAC inhibitors may contribute to the antitumour activity of these
compounds.48
Promoting histone acetylation as a neuroprotective strategy
Synaptic activity, acting via NMDA receptor (NMDAR) signaling, boosted antioxidant
defences through a coordinated pattern of gene expression that included the upregulation of
sulfiredoxin and sestrin 2. Both sulfiredoxin and sestrin 2 were induced by synaptic activity,
which also promoted the reduction of hyperoxidized Prxs.12 Simultaneous knock-down of
sulfiredoxin and sestrin 2 promoted neuronal vulnerability of neurons to oxidative stress.12
However, recent doubt has been cast on the ability of sestrin 2 to catalyze this reaction.49 In
the light of this study it may be that induction of sulfiredoxin is more significant with
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respect to reducing hyperoxidized Prxs than sestrin 2. In any case, both sulfiredoxin and
sestrin 2 are induced by inhibiting class I and II HDACs (Figs. 2B and 3A).
The inactivation of Prxs, through their hyperoxidation, is an indicator that the thioredoxin-
Prx system has become overwhelmed. Prxs are able to promote the resistance of neurons to
a diverse array of oxidative insults, including excitotoxicity and ischemia, as well as
exposure to β-amyloid, 1-methyl-4-phenylpyridinium (MPP+), ibotenate and peroxide.
2,8-10,50 As such, their oxidative inactivation may have deleterious effects on neurons in a
variety of pathological scenarios. In vitro, Prx hyperoxidation is associated with peroxide-
induced neuronal death,12 as well as NMDA receptor-dependent excitotoxic cell death.51
The hyperoxidation of Prxs may also take place in the brain in response to a variety of
oxidative trauma: we recently found that an episode of ischemia, followed by reperfusion,
induces strong hyperoxidation of Prxs in the mouse cortex.12 Increased levels of
hyperoxidized Prxs have also been observed during normal aging in the gerbil hippocampus.
13
Manipulation of the acetylation-deacetylation balance in neurons to favour acetylation may
prevent the oxidative inactivation of Prxs, although this requires further detailed
investigation. This effect may act in parallel with other protective effects of TSA treatment,
such as upregulation of p21waf1, which may contribute to TSA-induced protection of
embryonic neurons.29 Given that TSA has been shown to have neuroprotective effects in
stroke models in vivo,52,53 it would be of interest in the future to determine whether
ischemia-induced Prx hyperoxidation can be prevented by HDAC inhibition in vivo.
Materials and Methods
Tissue culture and drug treatment
Cortical rat neurons were cultured as described54 from E21 rats except that growth medium
contained B27 (Invitrogen). A single dose of anti-mitotic agent (AraC, 4.8 μM) was added
to the cultures at DIV4 to minimize glial numbers. Experiments were carried out after
neurons were cultured for 8–10 days during which cortical neurons develop a network of
processes, express functional NMDA-type and AMPA/kainate-type glutamate receptors, and
form synaptic contacts. Experiments were performed after transferring neurons at DIV8 into
defined medium lacking trophic support “TMo”.33 Trichostatin A (TSA) was used at a
concentration (1 μM) previously shown to have maximal neuroprotective effect,55 a fact
confirmed by a dose-response study in our experimental system (data not shown).
Induction of oxidative stress and assessment of cell death
An oxidative insult in the form of H2O2 (100 μM, stabilized solution: Sigma) was applied to
control cells or those that had been pre-treated with TSA for 8 h. Neurons were fixed after a
further 24 h and subjected to DAPI staining. Pictures were taken (blind) and cell death was
quantified using an automated technique employing a macro in ImageJ written by David
Stark from Nicholas Bazan's lab. The application of this macro was also performed blind.
Briefly, the assessment as to whether a nucleus was apoptotic or healthy is based on the
large difference in neuronal area between live and dead cells. Images are thresholded to
generate a binary black/white picture of nuclei, from which outlines of the nuclei were
obtained. The area from each outlined nucleus was then calculated in ImageJ. The area of an
apoptotic nucleus is typically 2–4 fold smaller than a healthy nucleus, enabling nuclei to be
scored as live or dead based on a threshold level set by the blind analyser. In cases where
multiple cells overlap, generating a large area, this area is divided by a figure approximating
to a single healthy nucleus, and the quotient of this figure used to determine the number of
healthy nuclei in this clump. Pictures were taken with a 10X objective; at this resolution
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chromatin fragmentation that is a feature of apoptotic nuclei is not generally thresholded into
individual outlines, rather a single outline around the multiple clumps is obtained. A final
filter was applied to ensure that tiny spots of fluorescent debris were not falsely counted as
an apoptotic nucleus. This technique has been validated in that it generates data that tightly
correlate with that obtained with blind manual counting. Using this technique, around 5,000
cells were counted per treatment, across three independent experiments.
Other techniques
For details of western blotting and qPCR and ChIP see.12 For ChIP, the anti-acetyl H4
antibody was from Upstate. The primer sequences used were: Sesn2: forward 5′ CAA ATA
TGC GGG TTT TGG TC 3′, reverse 5′ GAC AGC CCA GGG AGT CAT TA 3′. Srxn1:
forward 5′ TCT GTG TGT GTG TGT GTG TGG 3′, reverse 5′ GAG GAT GAG TCG
GCT CTC AG 3′. Txnip: forward 5′ AGC ACA CAC CCA AAC AAC C 3′, reverse 5′
TCT CCC ATT GGC TAC TGG 3′. Cycle times were optimised in order to ensure that the
reaction was stopped during the linear phase of amplification.
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Figure 1.
Synaptic activity triggers acetylation of histone H4 at the sestrin 2 promoter, but not the
sulfiredoxin promoter. (A and B) Neuronal cultures were treated with bicuculline (50 μM)
plus 4-aminopyridine (250 μM, denoted “BiC”) for 8 h followed by RNA extraction and q-
RT-PCR analysis of Sesn2 (A) and Srxn1 mRNA (B) normalized to Gapdh mRNA levels.
*p < 0.05 (two-tailed t-test, n = 3). (C–E) Chromatin immunoprecipitation (ChIP) analysis
of histone H4 acetylation of gene promoters in either control neurons or those treated with
BiC/4-AP. Stained agarose gels are shown of representative PCR reactions using primers
spanning the promoters of Sesn2 (C), Srxn1 (D) and Txnip (E). (F) Densitometric analysis
of PCR-amplified bands from all independent repeats (4) of the anti-acetyl H4 ChIP. The
purpose of this analysis is to demonstrate the reproducibility of the observed activity-
dependent Sesn2 promoter H4 acetylation. *p < 0.05 (two-tailed t-test, n = 4). (G) Synaptic
activity does not change global levels of histone acetylation. Neurons were treated with BiC/
4-AP for the indicated times followed by western blot analysis with antibodies specific for
the acetylated forms of histones H3 and H4.
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Figure 2.
Histone acetylation plays a role in the activity-dependent induction of sestrin 2 expression.
(A) Confirmation that treatment of neurons with TSA induces histone acetylation. Western
analysis of acetylation on histones H4 and H3 in neurons treated with TSA (1 μM here and
throughout) for the indicated times. (B) TSA treatment is sufficient to induce expression of
sestrin 2. qPCR based analysis of Sesn2 mRNA expression in neurons treated with TSA (8
h). *p < 0.05 (two-tailed t-test, n = 3). (C) The effect of TSA in inducing sestrin 2
expression is occluded by synaptic activity. Neurons were treated with BiC/4-AP in the
presence or absence of TSA for 8 h followed by RNA extraction and q-RT-PCR analysis of
Sesn2 (n = 3).
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Figure 3.
Histone acetylation is not involved in the activity-dependent induction of sulfiredoxin
expression. (A) TSA treatment is sufficient to induce expression of sulfiredoxin. qPCR
based analysis of Srxn1 mRNA expression in neurons treated with TSA (8 h, two-tailed t-
test, n = 3). (B) The effect of TSA in inducing sulfiredoxin expression is not occluded by
synaptic activity. Neurons were treated with BiC/4-AP in the presence or absence of TSA
for 8 h followed by RNA extraction and q-RT-PCR analysis of Srxn1 (n = 3).
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Figure 4.
Inhibiting histone deacetylases may promote the reduction of levels of hyperoxidized Prxs
and protect against oxidative insults. (A) TSA treatment is sufficient to induce expression of
sestrin 2 and sulfiredoxin protein. Neurons were treated with TSA for 8 h followed by
western analysis of sulfiredoxin and sestrin 2 expression. Densitometric analysis of ECL-
developed blots is shown for sestrin 2 (left) and sulfiredoxin (right). *p < 0.05 (two-tailed t-
test, n = 4). Inset shows an example blot. (B and C) TSA promotes the recovery of
hyperoxidized PrxII-SO2/3H following a 1 h exposure to H2O2 (100 μM). Neurons were
treated with TSA as indicated for 8 h prior to H2O2 exposure. Washout period was 16 h after
which cell lysates were prepared for western analysis of PrxII-SO2/3H levels using an
antibody specific for the hyperoxidized form of 2-Cys Prxs. To control for loading, blots
were stripped and re-probed with an antibody against 2-Cys Prxs. (B) shows an example
blot; (C) shows quantitation of all blots performed (*p < 0.05 compared to pre-washout
level, two-tailed t-test, n = 5). (D) TSA treatment protects neurons against peroxide-induced
apoptosis. Neurons were pre-treated with TSA or vehicle for 8 h prior to the application of
H2O2 (100 μM). Neurons were fixed after a further 24 h and subjected to DAPI staining and
cell death quantified blind (see Materials and Methods) and expressed as the number of
apoptotic nuclei as a percentage of the total. (*p < 0.05, two-tailed t-test, n = 3). Lower
panels show example pictures of DAPI-stained nuclei, scale bar represents 50 μm.
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